Similarly, the phase 3 nivolumab CheckMate 459 trial showed a trend towards a higher objective response rate (ORR) in patients with advanced hepatocellular carcinoma who had high PD-L1 expression level (TPS ≥ 1%), albeit not statistically significant (ORR 28% vs 12%) ( 26 ).
← all excerpts
Potential predictive biomarkers in antitumor immunotherapy: navigating the future of antitumor treatment and immune checkpoint inhibitor efficacy.
1
—
—